“ALF-5755, coming from a major discovery in the
laboratories of INSERM, is a unique First-in-Class drug
candidate which could revolutionize T2DM patient’s management.
Its mechanism of action targets the root cause of the disease: appearance of insulin resistance during aging and depending of the life style More than an exceptional human experience,
we live in very exciting times as THAC is successfully speeding up
its clinical development and growth, with tremendous innovation
for the benefit of patients – the commitment of one life”.
Pr. Christian Bréchot, Chairman
The mission of THAC is to develop a First-In-Class drug candidate to address Type 2 Diabetes Mellitus (T2DM) and severe complications
THAC aims to change the way patient care and healthy aging are addressed by primarily focusing on Type 2 Diabetes Mellitus (T2DM) and its severe complications, with the potential to further address other age-related diseases.
THAC develops a range of first-in-class drug candidates to address insulin resistance, the root cause of T2DM, by acting on gut microbiota for better patient care and disease management.
THAC drug candidates, potential game changers for the treatment of Type 2 diabetes mellitus (T2DM)
THAC envisions that by acting on gut microbiota and fighting insulin resistance, the root cause of T2DM with its drug candidates, a major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as diabetic neuropathy (e.g. diabetic foot wounds, amputations).
ALF-5755, the active ingredient of THAC drug candidates, is a first-in-class, first-in-man, GMP-produced recombinant bio-protein (17kDA) with a unique and innovative mechanism of action.
THAC drug candidate’ local activity on the microbiota is complementary to its systemic mechanism of action on other extracellular matrixes.
Insulin resistance, the root cause of T2DM
Aging is a natural process characterized by many cellular and molecular changes including inflammation and oxidative stress. Though physiological, these asymptomatic changes eventually lead to the development of insulin-resistance, a major risk factor for age-related diseases. Amongst them, T2DM and its complications.
Inactivity, overnutrition and to a lesser extent genetics are to add to aging as the main drivers for inflammation and oxidative stress (through the production of reactive oxygen species-ROS). These latter lead to insulin resistance which is responsible to the blood glucose increase, enhancing hyperglycaemia and hyperinsulinemia.
Insulin resistance starts early in life, is silent and asymptomatic for many years, may lead to severe complications and can cause premature death.
Insulin resistance is common to many age-related diseases such as cancer, liver diseases, dyslipidemia, diabetes and prediabetes, Alzheimer’s disease, polycystic ovary syndrome and cardiovascular diseases.